Kibel AS et al. (2007) Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol 177: 1777–1781
There is currently no standard adjuvant therapy for patients at high risk of disease recurrence or distant metastases following radical prostatectomy. Kibel et al., therefore, performed a multi-institutional, phase II pilot study of the systemic adjuvant docetaxel, which has shown survival benefits for patients with hormone-refractory prostate carcinoma in randomized controlled trials.
The trial included 77 patients who had undergone radical prostatectomy for localized disease, and who had a risk of biochemical recurrence within 3 years of ≥50%. Postoperatively, 50 (65%) of 77 patients had positive seminal vesicles, 29 (38%) of 77 had positive lymph nodes, and 50 (65%) of 77 had positive surgical margins. Patients underwent six 28-day cycles of 35 mg/m2 intravenous docetaxel infusions (administered on days 1, 8 and 15 of each cycle) with 10 mg dexamethasone pretreatment. Patients were evaluated weekly during treatment cycles, and were followed up every 3 months after treatment.
At the median follow-up (29.2 months, range 1.3–39.2 months), 46 (60.5%) out of 76 patients in the final analysis had disease progression. Median progression-free survival was 15.7 months, compared with a nomogram-predicted progression-free survival of 10.0 months. Grade I/II toxicity occurred in 54 (70%) patients, grade III toxicity occurred in 20 (26%) patients and grade IV toxicity occurred in 3 (4%) patients.
The authors conclude that adjuvant docetaxel increases progression-free survival with acceptable toxicity in high-risk patients, and suggest that a phase III trial investigating the efficacy of adjuvant androgen deprivation, with or without docetaxel, is warranted.
Rights and permissions
About this article
Cite this article
Adjuvant docetaxel following radical prostatectomy improves progression-free survival. Nat Rev Urol 4, 405 (2007). https://doi.org/10.1038/ncpuro0844
Issue Date:
DOI: https://doi.org/10.1038/ncpuro0844